Screener / SEC EDGAR /CIK 0001070494 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Acadia Pharmaceuticals Inc ACAD

Compare with peers Embed
What it said it expected, against what it reported

1 target with a reported result

Releases of the last 3 years
Above the range 0 above the last range given
Within the range 1 of 1 range targets
Below the range 0 below the last range given

The numbers ACAD said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $1.22B to $1.28B release Feb 25, 2026
Kept $1.22B to $1.28B release May 6, 2026
Raised $1.24B to $1.30B release Aug 4, 2026
Lowered $505.00M to $520.00M release Nov 4, 2026
– Not reported yet
The company's words
Full Year 2026 Financial Guidance (GAAP): … Total revenues of $1.22 to $1.28 billion release Feb 25, 2026
Acadia is reaffirming its 2026 guidance as first provided on February 25, 2026: … Total revenues of $1.22 to $1.28 billion release May 6, 2026
- Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance of $760 to $790 million release Aug 4, 2026
- Raises 2026 DAYBUE net sales guidance to $505–$520 million; narrows NUPLAZID range and total revenue range release Nov 4, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $1.03B to $1.09B release Feb 26, 2025
Kept $1.03B to $1.09B release May 7, 2025
Lowered $665.00M to $690.00M release Aug 6, 2025
Raised $1.07B to $1.09B release Nov 5, 2025
$1.07B
10-K filed 2026-02-26
Within the range
The company's words
Full Year 2025 Financial Guidance … Total Revenues (U.S. only) of $1.03 to $1.095 billion release Feb 26, 2025
Full Year 2025 Financial Guidance … Total Revenues (U.S. only) of $1.03 to $1.095 billion. release May 7, 2025
- Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance release Aug 6, 2025
Acadia is updating its 2025 guidance: … Total Revenues in the range of $1.070 to $1.095 billion, compared with the prior guidance range of $1.045 to $1.095 billion * . release Nov 5, 2025
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
  • Revenue, Fiscal 2024 (ended Dec 31, 2024): said $600.00M to $610.00M, reported $957.80M. The company's words

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-27), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ACAD/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.